Your browser doesn't support javascript.
loading
Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study.
Visser, Nicole C M; van der Putten, Louis J M; van Egerschot, Alex; Van de Vijver, Koen K; Santacana, Maria; Bronsert, Peter; Hirschfeld, Marc; Colas, Eva; Gil-Moreno, Antonio; Garcia, Angel; Mancebo, Gemma; Alameda, Francesc; Krakstad, Camilla; Tangen, Ingvild L; Huvila, Jutta; Schrauwen, Stefanie; Koskas, Martin; Walker, Francine; Weinberger, Vit; Minar, Lubos; Hausnerova, Jitka; Snijders, Marc P L M; van den Berg-van Erp, Saskia; Matias-Guiu, Xavier; Trovik, Jone; Amant, Frédéric; Massuger, Leon F A G; Bulten, Johan; Pijnenborg, Johanna M A.
Afiliação
  • Visser NCM; Department of Pathology, Radboud University Medical Centre, 6500HB, Nijmegen, the Netherlands; Radboud Institute for Molecular Life Sciences, 6500HB, Nijmegen, the Netherlands. Electronic address: Nicole.Visser@radboudumc.nl.
  • van der Putten LJM; Department of Obstetrics and Gynaecology, Radboud University Medical Centre, 6500HB, Nijmegen, the Netherlands.
  • van Egerschot A; Department of Pathology, Radboud University Medical Centre, 6500HB, Nijmegen, the Netherlands.
  • Van de Vijver KK; Department of Pathology, Ghent University Hospital, 9000, Ghent, Belgium.
  • Santacana M; Department of Pathology and Molecular Genetics and Oncological Pathology Group, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLLEIDA, CIBERONC, 25198, Lleida, Spain.
  • Bronsert P; Institute for Surgical Pathology, Medical Centre-University of Freiburg, 79085, Freiburg, Germany; Comprehensive Cancer Centre Freiburg, Medical Centre-University of Freiburg, 79106, Freiburg, Germany; Faculty of Medicine, University of Freiburg, 79085, Freiburg, Germany.
  • Hirschfeld M; Department of Obstetrics and Gynaecology, University Medical Centre Freiburg, 79106, Freiburg, Germany; German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), 69120, Heidelberg, Germany.
  • Colas E; Biomedical Research Group in Gynaecology, Vall Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, CIBERONC, 08193, Barcelona, Spain.
  • Gil-Moreno A; Biomedical Research Group in Gynaecology, Vall Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, CIBERONC, 08193, Barcelona, Spain; Gynecological Department, Vall Hebron University Hospital, CIBERONC, 8035, Barcelona, Spain.
  • Garcia A; Pathology Department, Vall Hebron University Hospital, 8035, Barcelona, Spain.
  • Mancebo G; Department of Obstetrics and Gynaecology, Hospital del Mar, 8003, Barcelona, Spain.
  • Alameda F; Department of Pathology, Hospital del Mar, 8003, Barcelona, Spain.
  • Krakstad C; Department of Obstetrics and Gynaecology, Haukeland University Hospital, 5021, Bergen, Norway; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, 5021, Bergen, Norway.
  • Tangen IL; Department of Obstetrics and Gynaecology, Haukeland University Hospital, 5021, Bergen, Norway; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, 5021, Bergen, Norway.
  • Huvila J; Department of Pathology, University of Turku, 20500, Turku, Finland.
  • Schrauwen S; Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, University Hospital Gasthuisberg, 3000, Leuven, Belgium.
  • Koskas M; Obstetrics and Gynaecology Department, Bichat-Claude Bernard Hospital, 75877, Paris, France.
  • Walker F; Pathology Department, Bichat-Claude Bernard Hospital, 75877, Paris, France.
  • Weinberger V; Department of Obstetrics and Gynaecology, University Hospital Brno, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic.
  • Minar L; Department of Obstetrics and Gynaecology, University Hospital Brno, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic.
  • Hausnerova J; Department of Pathology, University Hospital Brno, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic.
  • Snijders MPLM; Department of Obstetrics and Gynaecology, Canisius-Wilhelmina Hospital, 6500, GS, Nijmegen, the Netherlands.
  • van den Berg-van Erp S; Department of Pathology, Canisius-Wilhelmina Hospital, 6500, GS, Nijmegen, the Netherlands.
  • Matias-Guiu X; Department of Pathology and Molecular Genetics and Oncological Pathology Group, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLLEIDA, CIBERONC, 25198, Lleida, Spain.
  • Trovik J; Department of Obstetrics and Gynaecology, Haukeland University Hospital, 5021, Bergen, Norway; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, 5021, Bergen, Norway.
  • Amant F; Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, University Hospital Gasthuisberg, 3000, Leuven, Belgium; Department of Gynaecologic Oncology, Centre Gynaecologic Oncology Amsterdam (CGOA), Netherlands Cancer Institute and Amsterdam University Medical Centres, Academic Me
  • Massuger LFAG; Department of Obstetrics and Gynaecology, Radboud University Medical Centre, 6500HB, Nijmegen, the Netherlands.
  • Bulten J; Department of Pathology, Radboud University Medical Centre, 6500HB, Nijmegen, the Netherlands.
  • Pijnenborg JMA; Department of Obstetrics and Gynaecology, Radboud University Medical Centre, 6500HB, Nijmegen, the Netherlands.
Hum Pathol ; 89: 90-98, 2019 07.
Article em En | MEDLINE | ID: mdl-31054899
ABSTRACT
Discrimination between low- and high-grade endometrial carcinomas (ECs) is clinically relevant but can be challenging for pathologists, with moderate interobserver agreement. Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) is an oncofoetal protein that is associated with nonendometrioid endometrial carcinomas but has been limited studied in endometrioid carcinomas. The aim of this study is to investigate the diagnostic and prognostic value of IMP3 in the discrimination between low- and high-grade ECs and its added value to L1CAM. IMP3 and L1CAM expression was assessed in tumors from 378 patients treated for EC at 1 of 9 participating European Network for Individualised Treatment of Endometrial Cancer centers. IMP3 was expressed in 24.6% of the tumors. In general, IMP3 was more homogeneously expressed than L1CAM. IMP3 expression was significantly associated with advanced stage, nonendometrioid histology, grade 3 tumors, deep myometrial invasion, lymphovascular space invasion, distant recurrences, overall mortality, and disease-related mortality. Simultaneous absence of IMP3 and L1CAM expression showed the highest accuracy for identifying low-grade carcinomas (area under the curve 0.766), whereas simultaneous expression of IMP3 and L1CAM was strongly associated with high-grade carcinomas (odds ratio 19.7; 95% confidence interval 9.2-42.2). Even within endometrioid carcinomas, this combination remained superior to IMP3 and L1CAM alone (odds ratio 8.6; 95% confidence interval 3.4-21.9). In conclusion, IMP3 has good diagnostic value and together with L1CAM represents the optimal combination of diagnostic markers for discrimination between low- and high-grade ECs compared to IMP3 and L1CAM alone. Because of the homogenous expression of IMP3, this marker might be valuable in preoperative biopsies when compared to the more patchy L1CAM expression.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Neoplasias do Endométrio / Gradação de Tumores Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Hum Pathol Assunto da revista: PATOLOGIA Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Neoplasias do Endométrio / Gradação de Tumores Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Hum Pathol Assunto da revista: PATOLOGIA Ano de publicação: 2019 Tipo de documento: Article
...